Navigation Links
Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
Date:10/25/2012

BOSTONAspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but has no effect on patients who lack the mutation, Dana-Farber Cancer Institute scientists report in the Oct. 25 issue of the New England Journal of Medicine.

In a study involving more than 900 patients with colorectal cancer, the researchers found that, for patients whose tumors harbored a mutation in the gene PIK3CA, aspirin use produced a sharp jump in survival: five years after diagnosis, 97 percent of those taking aspirin were still alive, compared to 74 percent of those not using aspirin. By contrast, aspirin had no impact on five-year survival rates among patients without a PIK3CA mutation.

"Our results suggest that aspirin can be particularly effective in prolonging survival among patients whose colorectal cancer tests positive for a mutation in PIK3CA," said the study's senior author, Shuji Ogino, MD, PhD, of Dana-Farber, Brigham and Women's Hospital, and the Harvard School of Public Health. "For the first time, we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy." He cautions that the results need to be replicated by other researchers before they can be considered definitive.

While aspirin is often prescribed for colorectal cancer patients, doctors haven't been able to predict which patients will actually benefit from the treatment. The new finding suggests that the survival benefit is limited to the 20 percent whose tumors have the PIK3CA mutation.

For the remaining patients, aspirin may still be used, but it is likely to be much less effective and can sometimes lead to gastrointestinal ulcers and stomach bleeding.

The study was prompted by previous research that suggested that aspirin blocks an enzyme called PTGS2 (cyclooxygenase-2), causing a slowdown in the signaling activity of another enzyme, PI3K. That led researchers to hypothesize that aspirin could be especially effective against colorectal cancers in which the PIK3CA gene which provides a subunit of PI3K is mutated.

To conduct the study, investigators obtained data on 964 patients with rectal or colon cancer from the Nurses' Health Study and the Health Professionals Follow-up Study long-term tracking studies of the health of tens of thousands of people. The data included information on the patients' use of aspirin after diagnosis and the presence or absence of PIK3CA mutations in their tumor tissue.

The study, which combines the study of disease-related genes and research into large populations of individuals, represents a new, hybrid field which Ogino has termed molecular pathology epidemiology. "The field may help us bring together information from two frontiers of cancer research at both the molecular and population levels in ways that are beneficial to patients," he said.


'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Researchers Find Gene Mutations That May Be a Key to Autism
3. Mayo Clinic breast cancer study finds new type of mutation
4. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
5. Cancer may require simpler genetic mutations than previously thought
6. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
7. Study sheds new light on role of genetic mutations in colon cancer development
8. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
9. Study finds new gene mutations that lead to enlarged brain size, cancer, autism, epilepsy
10. Gene Mutation Linked to Facial, Skull Abnormalities
11. Mutation in gene IDH a possible target for AML treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... Standards Consortium (CDISC) announces today the open availability of a new CDISC ... and catalogs for registering clinical trials. This innovative standard will make it ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
(Date:4/28/2016)... ... 28, 2016 , ... One way to ignore solid evidence is to dismiss ... we toss the baby out with the bathwater when we ignore all studies because ... studies and otherwise making better use of education policy research. , “When readers heed ...
(Date:4/28/2016)... ... 28, 2016 , ... Point Source Audio® (PSA) , ... announced today that the US Patent Office has approved its patent submission that ... innovative design creates a lightweight and modular audio headset that has been said ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... containerization, today announced it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, ... , Held at Hilton Union Square, this will be MobileIron’s 6th Mobile First ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... , April 27, 2016 ... over USD 2.14 billion by 2022, according to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... advancement affecting the efficiency and accuracy delivered by ... persistent demand for novel urinalysis instruments and consumables. ...
(Date:4/26/2016)... CHICAGO , April 26, 2016 Hill-Rom Holdings, ... to a management presentation at the Deutsche Bank 41 st ... at 2:50 p.m. EDT. You are invited to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas ... one hour after conclusion of the live event and accessible ...
Breaking Medicine Technology: